Recent improvement in survival of patients with multiple myeloma: Variation by ethnicity

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1083-1089

  Pulte, Dianne ^a,b   Redaniel, Maria Theresa ^c   Brenner, Hermann ^a   Jansen, Lina ^a   Jeffreys, Mona ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Disparity; Myeloma; Period analysis; Survival

Indexed keywords

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; ETHNIC GROUP; ETHNICITY; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PACIFIC ISLANDER; PRIORITY JOURNAL; RACE; SURVIVAL; AGED; CANCER REGISTRY; ETHNOLOGY; HISTORY; MIDDLE AGED; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ETHNIC GROUPS; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RISK FACTORS; SEER PROGRAM; YOUNG ADULT;

EID: 84899752470     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.827188     Document Type: Article

References (48)

1. Brenner H, Gondos A, Pulte D. R ecent major improvement in long-Term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
2. Brenner H, Gondos A, Pulte D. Expected survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009; 94: 270-275.
3. Turesson I, Velez R, Kristinsson SY, et al. Patterns of improved survival in patients with multiple myeloma in the twenty-fi rst century: A population-based study. J Clin Oncol 2010; 28: 830-834.
4. Wong S L, G u N, Banerjee M, et a l. The impact of socioeconomic status on cancer care and survival. J Clin Oncol 2011; 29(Suppl.): Abstract 6004.
5. Macartney S, Bishaw A, Fontenot K. Poverty rates for selected detailed race and Hispanic groups by state and place: 2007-2011. American Community Survey Briefs; February 2013. Available from: Www.census.gov/prod/2013pubs/ acsbr11-17.pdf
6. Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission. Available from: Www.seer.cancer.gov http://www.seer.cancer.gov
7. Kaya H, Peressini B, Jawed I, et al. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol 2012; 95: 64-70.
8. Mariotto A, Capocaccia R, Verdecchia A, et al. Projecting SEER cancer survival rates to the US: An ecological regression approach. Cancer Causes Control 2002; 13: 101-111.
9. Bone Marrow and Cord Blood Donation and Transplantation. L ast updated: 18 May 2011. Available from: Http://bloodcell.transplant. hrsa.gov/index.htm
10. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 1961; 6: 101-121.
11. Henson DE, Ries LA. The relative survival rate. C ancer 1995; 76: 1687-1688.
12. Ederer F, Heise H. I nstructions to IBM 650 programmers in processing survival computations. Methodological note No. 10. Bethesda, MD: National Cancer Institute; 1959.
13. Arias E. U nited States life tables, 2000. N atl Vital Stat Rep 2002; 51: 1-39.
14. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996; 78: 2004-2010.
15. Brenner H, Gefeller O, Hakulinen T. Period analysis for ' up-To-date' cancer survival data: Empirical evaluation, computational realisation and applications. Eur J Cancer 2004; 40: 326-335.
16. Coleman M P, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK 1995-2007 (the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data. Lancet 2011; 377: 127-138.
17. Brenner H, Hakulinen T. Up-To-date long-Term survival curves of patients with cancer by period analysis. J Clin Oncol 2002; 20: 826-832.
18. Brenner H. and Hakulinen T. Up-To-date and precise estimates of cancer patient survival: Model-based period analysis. Am J Epidemiol 2006; 164: 689-696.
19. van de Schans SA, Gondos A, van Spronsen DJ, et al. Improving relative survival, but remaining differences in survival for non-Hodgkin's lymphoma across Europe and the United States from 1990 to 2004. J Clin Oncol 2011; 29: 192-199.
20. Pulte D, Gondos A, Brenner H. T rends in 5-And 10-year survival after diagnosis with childhood hematologic malignancies in the United States 1990-2004. J Natl Cancer Inst 2008; 100: 1301-1309.
21. Corazziari I, Quinn M, Capocacci R. S tandard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40: 2307-2316.
22. Dickman P W, Sloggett A, Hills M, Hakulinen T. R egression models for relative survival. Stat Med 2004; 23: 51-64.
23. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 851: 1860-1873.
24. Hadley J. S icker and poorer-The consequences of being uninsured: A review of research on the relationship between health insurance, medical care use, health, work, and income. Med Care Res Rev 2003; 60: 3S-75S.
25. Health, United States, 2012: With special feature on emergency care. Hyattsville, MD: National Center for Health Statistics; 2013.
26. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: A population-based study. Blood 2010; 116: 5501-5506.
27. Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis, and progression of monoclonal gammopathy of undetermined significance and mulitple myeloma bewtwen blacks and whites. Leukemia 2012; 26: 609-614.
28. Joshua TV, Rizzo DJ, Yhang MJ, et al. Access to hematopoietic stem cell transplantation: Effect of race and sex. Cancer 2010; 116: 3469-3476.
29. Hari PN, Majhail NS, Yhang MJ, et al. Race and outcomes of autologous hematopoietic cell tranplantations for multiple myeloma. Biol Blood Marrow Transplant 2010; 16: 395-402.
30. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. C A Cancer J Clin 2010; 60: 277-300.
31. Abou-Jawde RM, Baz R, Walker E, et al. The role of race, socioeconomic status, and distance traveled on outcomes of African-American patients with multiple myeloma. Haematologica 2006; 91: 1410-1413.
32. Modiano MR, Villar-Werstler P, Crowley J, et al. Evaluation of race as a prognostic factor in multiple myeloma. J Clin Oncol 1996; 14: 974-977.
33. Savage D, Lindenbaum J, Van Ryzin J, et al. Race, poverty, and survival in multiple myeloma. Cancer 1984; 54: 3085-3094.
34. Attal M, Harousseau J L, Stoppa A M, et a l. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francis du Myeloma. N Engl J Med 1996: 335: 91-97.
35. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
36. Dimopoulous M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
37. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
38. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisode chemotherapy plus thalidomide compared to melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367: 825-831.
39. Saraf S, Patel PR, Ozer H, et al. Favorable responses to novel agents for multiple myeloma in African American patients. Blood 2011; 118(Suppl. 1): Abstract 4213.
40. Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapse, refractory multiple myeloma. Blood 2005; 106: 2977-2981.
41. Ogawa Y, Tobinai K, Ogura M, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci 2008; 99: 140-144.
42. US Census Bureau Migration by race and Hispanic origin: 1995 to 2000 Census 2000 Special Reports Issued 0ctober, 2003. Available from: Www.census.gov/population/hispanic/publications/
43. Grieco EM, Acosta YD, de la Cruz GP, et al. The foreign-born population in the United States: 2010. American Community Survey Reports. Issued May 2012. Available from: Www.census.gov/ prod/2012pubs/acs-19.pdf
44. DeNavas-Walt C, Proctor B D, Smith J C. U S Census Bureau, Current Population Reports, P60-238. Income, poverty, and health insurance coverage in the United States: 2009. Washington, DC: US Government Printing Office; 2010.
45. Huang K, Carrasquillo O. The role of citizenship, employment, and socioeconomic characteristics in health insurance coverage among Asian subgroups in the United States. Med Care 2008: 46: 1093-1098.
46. Fuller-Th omson E, Noack AM, George U. Health decline among recent immigrants to Canada: Fi ndings from a nationally-representative longitudinal survey. Can J Public Health 2011; 102: 273-280.
47. Hacker K, Chu J, Leung C, et al. The impact of immigration and customs enforcement on immigrant health: Perceptions of immigrants in Everett, Massachusetts, USA. Soc Sci Med 2011; 73: 586-594.
48. Kullgren JT. Restrictions on undocumented immigrants ' access to health services: The public health impli